AZ, MSD’s Koselugo is first EU therapy for neurofibromatosisThe European Commission has approved AstraZeneca and MSD’s Koselugo for a rare genetic condition that causes tumours to Share XAZ, MSD’s Koselugo is first EU therapy for neurofibromatosishttps://pharmaphorum.com/news/az-msds-koselugo-is-first-eu-therapy-for-neurofibromatosis/
